About
Anto Biosciences develops multimodal foundation models that make the gut microbiome computable for drug development. Its intended customers are pharmaceutical and biotechnology drug developers seeking better toxicity and efficacy prediction across populations; its differentiation is quality-aware sparsification, causal microbial-ecosystem modeling, and AI-guided optimization of drug molecules.
Market
Anto competes in AI-enabled computational biology and microbiome-focused drug discovery, positioning itself as a foundation-model platform that makes noisy gut-microbiome and multi-omics data usable for drug development. Its differentiation is the combination of large multimodal models, quality-aware sparsification and tokenization, causal ecosystem modeling, and intervention-oriented validation to predict microbiome-driven drug toxicity and efficacy rather than focusing solely on developing a single microbiome therapeutic.
Anto's ideal customers are pharmaceutical and biotechnology companies developing drugs whose efficacy, toxicity, or population response may be affected by the gut microbiome. The likely buyers are R&D leaders and teams in drug discovery, translational medicine, pharmacology, toxicology, and precision medicine, particularly at organizations with substantial multi-omics and clinical-development programs.
At a Glance
Problem
Anto Biosciences addresses a blind spot in drug development: the gut microbiome can determine whether a drug is effective, ineffective, or toxic, yet conventional development largely treats it as noise. The company says more than 1 billion people take drugs whose outcomes are influenced by the microbiome, while microbiome datasets are roughly 99% noise, too sparse, high-dimensional, and confounded for conventional computational methods to use reliably.
The killer use case is improving drug success across diverse patient populations. Microbes can metabolize drugs before they reach their targets, activate otherwise inactive compounds, create toxic metabolites, and alter immune responses. Anto positions this variability as a root cause of failed trials, preventable adverse reactions, and abandoned treatments, with billions spent developing drugs that do not work consistently across populations.
Product / Service
Anto is building multimodal foundation models for microbial communities and a computational platform for drug development. Its approach uses quality-aware, goal-directed sparsification to remove low-quality microbiome data and retain the small fraction with predictive value, then combines large-scale multi-omics, causal modeling, and more than 100,000 interventional trajectories with AI-guided laboratory validation.
The company’s Darwin model series is intended to predict drug toxicity and efficacy across populations and optimize molecules for broader efficacy. More broadly, Anto aims to forecast microbial-ecosystem dynamics, model counterfactual intervention outcomes, and support inverse design of microbial therapies. The public evidence points to a research and partnership-led platform, rather than a marketed therapeutic product, with the benefit of turning noisy microbiome data into actionable drug-design and clinical-development insight.
Market
Anto competes at the intersection of AI drug discovery, computational biology, multi-omics, and microbiome therapeutics. Its distinctive positioning is a full-stack, microbiome-focused foundation-model platform aimed at explaining and correcting microbiome-driven drug response. The available company and accelerator materials do not name specific direct competitors, so a reliable competitor list cannot be established from the public evidence reviewed; its closest competitive alternatives are likely broader AI drug-discovery, pharmacology, and microbiome-data platforms.
Anto appears to be an early-stage company: YC lists it as a Fall 2025 company with four employees in San Francisco, and a funding database reports $500,000 raised in June 2026, including a seed investment associated with Tekedia Capital. A third-party profile describes revenue through partnerships with pharmaceutical companies and research institutions under service agreements, suggesting a partnership-led commercial model rather than a purely pre-revenue venture, but no customer names, revenue figures, or product-scale metrics are disclosed in the available sources.
Founders & Leadership
Funding History
Y Combinator
Recent News
Tekedia Capital announced an investment in Anto Biosciences, which is developing AI foundation models to make the gut microbiome computable for drug development. The coverage highlights Anto’s sparsification algorithms and Darwin model series for predicting drug toxicity and efficacy across populations.
Y Combinator profiled Anto as a Fall 2025 company building a foundation model for microbial communities. Its stated product predicts drug toxicity and efficacy across diverse populations and aims to optimize molecules for broader efficacy.
Tracxn records Anto Biosciences’ $500,000 seed round on September 29, 2025, with Y Combinator listed as the investor. The record identifies this as the company’s only reported funding round.
LabCentral’s AI BioHub cohort coverage featured Anto Biosciences as building a multimodal foundation model for the human “second genome,” the gut microbiome, to predict how gut bacteria affect drug development.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
The company has not publicly disclosed specific pricing or revenue streams. Its stated commercial direction is a business-to-business drug-development offering for pharmaceutical and biotechnology teams, using models to predict toxicity and efficacy and optimize molecules; the exact licensing, software-access, or partnership model remains undisclosed.